Risk-based monitoring could be a boon to CROs

Now that the FDA is encouraging drugmakers to consider risk-based monitoring for clinical trials, CROs that have already invested in adaptive trials could stand to benefit. As North Carolina's News & Observer points out, getting into the risk-based business would require up-front investment by drug developers, but the likes of Quintiles ($Q), INC Research and PRA are already well-versed in the method, positioning them to cash in on the trend. Report

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.